ADVFN - Advanced Financial Network.
HOME» NYSE » A » ABT Stock Price » ABT Stock News

Abbott Labs Share News

 Abbott Laboratories Stock Price
ABT Stock Price
 Abbott Laboratories Stock Chart
ABT Stock Chart
 Abbott Laboratories Stock News
ABT Stock News
 Abbott Laboratories Company Information
ABT Company Information
 Abbott Laboratories Stock Trades
ABT Stock Trades

WSJ BLOG/Health: Medical Group Blinks Amid Criticism Over Drug-Data Disclosure

(This story has been posted on The Wall Street Journal Online's Health Blog at By Peter Loftus A European medical society that hosts a major conference had planned to just let members and attendees -- including analysts and investors -- get an early look today at the results of some potentially market-moving studies. But after howls from critics saying that policy amounted to selective disclosure of data of Hepatitis C drugs being developed by Abbott Laboratories, Bristol-Myers Squibb and Gilead Sciences, the European Association for the Study of the Liver blinked, Dow Jones Newswires reports. The EASL now plans to publicly release summaries of most of the studies online on April 4, two weeks ahead of the meeting in Barcelona. Some won't be released until the April 18-22 event, but at the same time for everyone except media reporters, who'll get the typical early look to help them produce their stories. (EASL had planned to ban media registered to attend the meeting from reporting on the summaries until the event.) "EASL is making these changes in light of recent criticism of its proposed policy," the group said in a written statement. This isn't the first time a medical group has changed how it presents drug data at meetings -- a fraught issue that, when mishandled, can put organizations at risk of running afoul of securities laws. The American Society of Clinical Oncology, for instance, changed its policy and posts most study summaries online ahead of its annual scientific meeting. It used to distribute them to participants weeks ahead of the conference, but banned media from reporting on the contents until the event. "I think the days of conferences engaging in selective release of important study results are probably over," Scott Gottlieb, a physician and resident fellow at the American Enterprise Institute, tells Dow Jones. -For continuously updated news from The Wall Street Journal, see at

Stock News for Abbott Labs (ABT)
07/20/201615:36:00Abbott Results, Helped by Product Launches, Top Views
07/20/201611:10:00St. Jude Medical Logs Double-Digit Sales Growth -- Update
07/20/201609:20:00Abbott Labs Profit Tops Views
07/20/201609:03:00Abbott Labs Profit Tops Views
07/20/201608:30:00St. Jude Medical Logs Double-Digit Sales Growth
07/20/201608:25:00St. Jude Medical Logs Double-Digit Sales Growth
07/20/201607:52:30Current Report Filing (8-k)
07/20/201607:45:00Abbott Reports Second-Quarter 2016 Results
07/15/201612:49:00FDA Approves the Tecnis Symfony® Intraocular Lenses, the First...
07/14/201619:00:00Alere Expects to Restate Financial Results
07/14/201613:15:00Health Canada approves Abbott's Absorb™ bioresorbable stent, t...
07/13/201609:36:00U.S. Hot Stocks: Hot Stocks to Watch
07/12/201618:37:00FTC Requests Additional Info Before Approving Abbott Labs, St...
07/12/201616:33:46Current Report Filing (8-k)
07/11/201623:10:00Alere to Voluntarily Pull Blood-Monitoring Devices
07/11/201619:04:00Alere to Voluntarily Pull Blood-Monitoring Devices
07/06/201617:08:21Statement of Changes in Beneficial Ownership (4)
07/06/201617:07:54Statement of Changes in Beneficial Ownership (4)
07/06/201617:07:03Statement of Changes in Beneficial Ownership (4)
07/05/201623:53:00What's News: Business & Finance

Abbott Laboratories and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations